Cargando…

Adding Sodium–Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Hypoglycemia is an important event that could be related to increased mortality in patients with diabetes. The risk of hypoglycemia is not clearly illustrated to increase when Sodiumglucose co-transporter 2 (SGLT-2) inhibitors are used concomitantly with sulfonylureas. The present study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Meng, Liu, Qiaoshu, Jiang, Tiejian, Nizigiyimana, Paul, Lei, Minxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568344/ https://www.ncbi.nlm.nih.gov/pubmed/34744998 http://dx.doi.org/10.3389/fendo.2021.713192

Ejemplares similares

Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease
por: Jiang, Meng, et al.
Publicado: (2019)

Sulfonylurea-Induced Hypoglycemia in a Patient With Cirrhosis
por: Braet, Corey, et al.
Publicado: (2020)

Gut microbiota is associated with differential metabolic characteristics: A study on a defined cohort of Africans and Chinese
por: Nizigiyimana, Paul, et al.
Publicado: (2022)

Role of Octreotide in Sulfonylurea-Induced Hypoglycemia
por: Zafar, Sheema, et al.
Publicado: (2021)

Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
por: Li, Chun Xing, et al.
Publicado: (2023)

Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis
por: Zheng, Hanrui, et al.
Publicado: (2021)

Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
por: Wong, Chloe, et al.
Publicado: (2021)

Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
por: Zhang, Sha, et al.
Publicado: (2023)

Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials
por: Li, Daobo, et al.
Publicado: (2021)

Inhibition of acid sphingomyelinase activity ameliorates endothelial dysfunction in db/db mice
por: Jiang, Meng, et al.
Publicado: (2019)

Alpha‐mangostin improves endothelial dysfunction in db/db mice through inhibition of aSMase/ceramide pathway
por: Jiang, Meng, et al.
Publicado: (2021)

Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
por: Yang, Yinqiu, et al.
Publicado: (2020)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
por: Donnan, Jennifer R, et al.
Publicado: (2019)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective
por: Farahani, Pendar
Publicado: (2018)

Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis
por: Lai, Shih-Wei, et al.
Publicado: (2023)

Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
por: Akiyama, Hiroki, et al.
Publicado: (2023)

Meta-Analysis: Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents
por: Mattishent, Katharina, et al.
Publicado: (2021)

Natriuretic Hormones, Endogenous Ouabain, and Related Sodium Transport Inhibitors
por: Hamlyn, John M.
Publicado: (2014)

The Urinary Glucose Excretion by Sodium–Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis
por: Hu, Suiyuan, et al.
Publicado: (2022)

Sexual Dimorphism in Glucose and Lipid Metabolism during Fasting, Hypoglycemia, and Exercise
por: Hedrington, Maka S., et al.
Publicado: (2015)

SAT-LB110 Sulfonylurea-Induced Hypoglycemia: To Use Octreotide or Not
por: Romeu, Jose, et al.
Publicado: (2020)

Pharmacogenetics of Hypoglycemia Associated with Sulfonylurea Therapy in Usual Clinical Care
por: Mitchell, Sabrina L, et al.
Publicado: (2020)

A Case of Hypoglycemia With Concomitant Use of a Sulfonylurea and Clopidogrel
por: Ruiz, Brent, et al.
Publicado: (2022)

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
por: Wan, Ningning, et al.
Publicado: (2018)

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
por: Xie, Yan, et al.
Publicado: (2021)

The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
por: Liu, Xindong, et al.
Publicado: (2023)

A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
por: Sinha, Binayak, et al.
Publicado: (2022)

Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhang, Ailing, et al.
Publicado: (2021)

The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus
por: Brunton, S. A.
Publicado: (2015)

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials
por: Storgaard, Heidi, et al.
Publicado: (2014)

Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis
por: Wei, Wen, et al.
Publicado: (2022)

Influence and mechanism of sodium-glucose cotransporter-2 inhibitors on the cardiac function: study protocol for a prospective cohort study
por: Cao, Min-Jia, et al.
Publicado: (2023)

The effectiveness of octreotide at different doses for sulfonylurea-induced hypoglycemia following overdose
por: Gul, M, et al.
Publicado: (2007)

Stress Cardiomyopathy Induced by Refractory Hypoglycemia Due to Acute Sulfonylurea Intoxication
por: Shah, Binoy K, et al.
Publicado: (2023)

Sodium-Glucose Linked Transporter Inhibitors as a Cause of Euglycemic Diabetic Ketoacidosis on a Background of Starvation
por: Tauseef, Abubakar, et al.
Publicado: (2020)

Use of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetics: Are the Benefits Worth the Risks?
por: Fatima, Tehreem, et al.
Publicado: (2020)

Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis
por: Chen, Min, et al.
Publicado: (2016)

Recurrent Hypoglycemia Increases Anxiety and Amygdala Norepinephrine Release During Subsequent Hypoglycemia
por: McNay, Ewan
Publicado: (2015)

Altered Serum Amino Acid and Acylcarnitine Profiles in Hyperinsulinemic Hypoglycemia and Ketotic Hypoglycemia
por: Xu, Zhen-Ran, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lvrvf1r9rh22amphlmhlq3jpcb